arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

DBV Technologies S.A.

DBVT
$9.83 ▼ -0.15 (-1.55%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
29 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

DBV Technologies S.A. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4B
Dividend Yield —
Revenue Growth -42.3% ↗
Op. Margin None
ROIC -43.8% ↘
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 29.8x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.60M
↓ -42.3% —
Net Income Profit after all expenses
$-47.60M
↓ -75.8% —
Operating Margin Operating profit as % of sales
-134.3%
↑ +70.8% —
FCF / Share Free cash flow per share
$-0.12
↑ +2.6% —
Long-Term Debt Long-term obligations
$200.00K
↓ -60.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
10
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 29 quarters